2seventy bio, Inc. - Common Stock (NQ:TSVT)

5.000 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about 2seventy bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability ↗

September 25, 2024

2seventy bio halts enrollment in its KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval...

Via Benzinga

2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance

September 25, 2024

From 2seventy bio, Inc.

Via Business Wire

2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference

August 29, 2024

From 2seventy bio

Via Business Wire

A Preview Of 2seventy bio's Earnings ↗

March 04, 2024

Via Benzinga

2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress

August 07, 2024

From 2seventy bio, Inc.

Via Business Wire

2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024

August 05, 2024

From 2seventy bio, Inc.

Via Business Wire

3 Hidden Stock Gems That Wall Street Is Overlooking ↗

July 05, 2024

If you play the long game and have a suitable risk tolerance, you can find overlooked stock gems like these three.

Via InvestorPlace

Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma ↗

June 27, 2024

2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on...

Via Benzinga

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

June 26, 2024

From 2seventy bio, Inc.

Via Business Wire

2seventy bio to Participate in Upcoming Investor Conferences

May 23, 2024

From 2seventy bio, Inc.

Via Business Wire

TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024 ↗

May 08, 2024

TSVT stock results show that 2seventy bio met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

May 08, 2024

From 2seventy bio, Inc.

Via Business Wire

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

May 03, 2024

From 2seventy bio, Inc.

Via Business Wire

FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies ↗

April 19, 2024

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel

Via Benzinga

FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer ↗

April 05, 2024

FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior therapies. Extends progression-free survival by 13.3 months vs. standard...

Via Benzinga

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

April 01, 2024

From 2seventy bio, Inc.

Via Business Wire

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

April 05, 2024

From Bristol Myers Squibb

Via Business Wire

2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors

March 20, 2024

From 2seventy bio, Inc.

Via Business Wire

Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 18, 2024

Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates.

Via Benzinga

FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer ↗

March 18, 2024

FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 18, 2024

Via Benzinga

Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗

March 18, 2024

Shares of Nuvei Corp (NASDAQ: NVEI) rose sharply in today’s pre-market trading following a report indicating the company is in buyout talks with Advent International. Nuvei shares jumped 14.1% to...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

March 18, 2024

Pre-market stock movers are the perfect way to start the week as we dive into the biggest stories moving shares on Monday!

Via InvestorPlace

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy

March 15, 2024

From Bristol Myers Squibb

Via Business Wire

Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket ↗

March 15, 2024

Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings.

Via Benzinga

Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley ↗

March 07, 2024

Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.

Via Benzinga

TSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023 ↗

March 05, 2024

TSVT stock results show that 2seventy bio missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress

March 05, 2024

From 2seventy bio, Inc.

Via Business Wire

2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences

March 01, 2024

From 2seventy bio, Inc.

Via Business Wire

Earnings Scheduled For March 5, 2024 ↗

March 05, 2024

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.